⌕
Janux Therapeutics · JANX · Nasdaq
Tenet 74 · Solid
Compare
$10.92−3.96%At closeTenet 74 · Solid
$10.92−0.45 (−3.96%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Janux Therapeutics (JANX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 5.6% in FY25, net margin −1136.2%. Worth your attention in FY25: Share count (+163.4%) and Capex step-up ($1.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼5.6%
10.0
FY21→FY25CAGR +28.8%/yr
Net income ($M)▼64.7%
−113.6
FY21→FY25CAGR —
Free cash flow ($M)▼88.5%
−83.3
capex stepped upCAGR —
Diluted EPS▼43.0%
−1.83
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+163.4%

23.5mn → 62.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$1.0M

▲191% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)10.0Revenue0.0COGS10.0Gross profit−125.9R&D−41.8SG&A−157.7Op income44.0Tax & other−113.6Net income

-1136¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

Over this window: gross 100.0% → 100.0%. Net margin -1136.3% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
23,289.010,000.010,588.08,083.08,612.03,637.0▼5.6%+28.8%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
23,289.010,000.010,588.08,083.08,612.03,637.0▼5.6%+28.8%
Research & development
119,920.0125,896.068,388.054,922.053,441.026,237.0▲84.1%+48.0%
Selling, general & admin
42,931.041,771.041,047.026,140.022,262.010,329.0▲1.8%+41.8%
Total operating expenses
162,851.0167,667.0109,435.081,062.075,703.036,566.0▲53.2%+46.3%
Operating incomefeeds ROC rank
−139,562.0−157,667.0−98,847.0−72,979.0−67,091.0−32,929.0▼59.5%—
Other income, net
39,713.044,042.029,853.014,686.04,032.0257.0——
Pretax income
−99,849.0−113,625.0−68,994.0−58,293.0−63,059.0−32,672.0▼64.7%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−99,849.0−113,625.0−68,994.0−58,293.0−63,059.0−32,672.0▼64.7%—
Per share
Diluted EPSbuyback-sensitive
−1.59−1.83−1.28−1.32−1.52−1.39▼43.0%—
Diluted shares (mn)
63.0961.9753.7544.0241.4723.53▲15.3%+27.4%
Margins
Gross margin
100.0%100.0%100.0%100.0%100.0%100.0%▲0.0pp+0.0pp
Operating margin
−599.3%−1576.7%−933.6%−902.9%−779.0%−905.4%▼643.1pp−671.3pp
Net margin5th pct in Healthcare
−428.7%−1136.3%−651.6%−721.2%−732.2%−898.3%▼484.6pp−237.9pp
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Janux Therapeutics' revenue last fiscal year?

Janux Therapeutics reported revenue of $10.0M in fiscal 2025, down 5.6% from fiscal 2024.

What was Janux Therapeutics' net income?

Janux Therapeutics reported net income of −$113.6M in fiscal 2025, a net margin of −1136.3%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.